Buscar
01/11/2025
Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021
Cardozo, AR, Tibau, A, Liu, I, Han, J, Cliff, E, Kesselheim, A. Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2894. PMID:. IF:65.400(Q1/1D).
01/11/2025
Endoscopic-assisted maxillectomy: our experience in tumours affecting the posterior wall of the maxillary sinus
Casasayas, M, Holgado, A, León, X, Kolanczak, K, Pérez-Sempere, M, Quer, M, Gras-Cabrerizo, JR. Endoscopic-assisted maxillectomy: our experience in tumours affecting the posterior wall of the maxillary sinus. JOURNAL OF LARYNGOLOGY AND OTOLOGY. 2025; 139(11)DOI:10.1017/S0022215125102958. PMID:40734309. IF:0.800(Q3/8D).
01/11/2025
First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup))
Portu, M, Martinez-Recio, S, Barba, A, Gonzalez, A, López, L, Catasús, L, Majem, M. First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup)). Clinical Lung Cancer. 2025; 26(7)DOI:10.1016/j.clic.2025.07.013. PMID:40774920. IF:3.300(Q2/4D).
01/11/2025
Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024
Cardozo, AR, Kesselheim, A, Tibau, A. Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1886. PMID:. IF:65.400(Q1/1D).